Trial watch: Tumor-targeting monoclonal antibodies for oncological indications

OncoImmunology

Volumn 4, Issue 1, 2015, Pages 985940-

  Vacchelli, Erika ^a,b,c   Pol, Jonathan ^a,b,c   Bloy, Norma ^a,b,c   Eggermont, Alexander ^a   Cremer, Isabelle ^b,c,d   Fridman, Wolf Hervé ^b,c,d   Galon, Jérôme ^b,c,d,e   Marabelle, Aurélien ^a,b   Kohrt, Holbrook ^f   Zitvogel, Laurence ^a,b   Kroemer, Guido ^a,b,c,e,g   Galluzzi, Lorenzo ^a,b,c,e  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

bevacizumab; cetuximab; obinutuzumab; ramucirumab; rituximab; trastuzumab

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CATUMAXOMAB; CETUXIMAB; DENOSUMAB; EMD 273063; FLUOROURACIL; FOLINIC ACID; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IRINOTECAN; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OFATUMUMAB; OXALIPLATIN; PANITUMUMAB; PERTUZUMAB; PLACEBO; RAMUCIRUMAB; RITUXIMAB; SILTUXIMAB; TOSITUMOMAB; TRASTUZUMAB; TUMOR ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; COLORECTAL CARCINOMA; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GIANT CELL TUMOR; GLIOBLASTOMA; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; KIDNEY CANCER; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; LUNG CANCER; MANTLE CELL LYMPHOMA; MULTICENTER STUDY (TOPIC); MULTIPLE CANCER; MYELODYSPLASTIC SYNDROME; NEOPLASM; NEUROBLASTOMA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; STOMACH CARCINOMA; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

EID: 84938709400     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.985940     Document Type: Article

References (193)

1. S.S.Alkan. Monoclonal antibodies: the story of a discovery that revolutionized science and medicine. Nat Rev Immunol 2004; 4:153-6; PMID:15040588; dx.doi.org/10.1038/nri1265
2. L.M.Weiner, R.Surana, S.Wang. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27; PMID:20414205; dx.doi.org/10.1038/nri2744
3. F.Aranda, E.Vacchelli, A.Eggermont, J.Galon, W.H.Fridman, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27297; PMID:24701370; dx.doi.org/10.4161/onci.27297
4. L.Galluzzi, G.Kroemer, A.Eggermont. Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncoimmunology 2014; 3:in press
5. E.Vacchelli, A.Eggermont, J.Galon, C.Sautes-Fridman, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2:e22789; PMID:23482847; dx.doi.org/10.4161/onci.22789
6. E.Vacchelli, F.Aranda, A.Eggermont, J.Galon, C.Sautes-Fridman, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27048; PMID:24605265; dx.doi.org/10.4161/onci.27048
7. L.M.Weiner, A.S.Belldegrun, J.Crawford, A.W.Tolcher, P.Lockbaum, R.H.Arends, L.Navale, R.G.Amado, G.Schwab, R.A.Figlin. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 2008; 14:502-8; PMID:18223225; dx.doi.org/10.1158/1078-0432.CCR-07-1509
8. C.Ming Lim, R.Stephenson, A.M.Salazar, R.L.Ferris. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR head and neck cancer cells. Oncoimmunology 2013; 2:e24677; PMID:23894722; dx.doi.org/10.4161/onci.24677
9. P.J.Kaplan-Lefko, J.D.Graves, S.J.Zoog, Y.Pan, J.Wall, D.G.Branstetter, J.Moriguchi, A.Coxon, J.N.Huard, R.Xu Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther 2010; 9:618-31; PMID:20150762; dx.doi.org/10.4161/cbt.9.8.11264
10. F.Nimmerjahn, J.V.Ravetch. Fcgamma receptors: old friends and new family members. Immunity 2006; 24:19-28; PMID:16413920; dx.doi.org/10.1016/j.immuni.2005.11.010
11. P.Hubert, S.Amigorena. Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy. Oncoimmunology 2012; 1:103-5; PMID:22720225; dx.doi.org/10.4161/onci.1.1.17963
12. R.Houot, H.Kohrt, R.Levy. Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. Oncoimmunology 2012; 1:957-8; PMID:23162770; dx.doi.org/10.4161/onci.19974
13. T.Kute, J.R.StehleJr, D.Ornelles, N.Walker, O.Delbono, J.P.Vaughn. Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells. Oncoimmunology 2012; 1:810-21; PMID:23162748; dx.doi.org/10.4161/onci.20447
14. M.Winiarska, E.Glodkowska-Mrowka, J.Bil, J.Golab. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci 2011; 16:277-306; PMID:21196171; dx.doi.org/10.2741/3688
15. J.R.Dunkelberger, W.C.Song. Complement and its role in innate and adaptive immune responses. Cell Res 2010; 20:34-50; PMID:20010915; dx.doi.org/10.1038/cr.2009.139
16. P.F.Zipfel, C.Skerka. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009; 9:729-40; PMID:19730437; dx.doi.org/10.1038/nri2620
17. D.Seimetz. Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab). J Cancer 2011; 2:309-16; PMID:21716847; dx.doi.org/10.7150/jca.2.309
18. S.Armeanu-Ebinger, A.Hoh, J.Wenz, J.Fuchs. Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma. Oncoimmunology 2013; 2:e22620; PMID:23482411; dx.doi.org/10.4161/onci.22620
19. T.E.Witzig, L.I.Gordon, F.Cabanillas, M.S.Czuczman, C.Emmanouilides, R.Joyce, B.L.Pohlman, N.L.Bartlett, G.A.Wiseman, N.Padre Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453-63; PMID:12011122; dx.doi.org/10.1200/JCO.2002.11.076
20. M.S.Kaminski, J.Estes, K.R.Zasadny, I.R.Francis, C.W.Ross, M.Tuck, D.Regan, S.Fisher, J.Gutierrez, S.Kroll Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96:1259-66; PMID:10942366
21. B.Hughes. Antibody-drug conjugates for cancer: poised to deliver? Nat Rev Drug Discov 2010; 9:665-7; PMID:20811367; dx.doi.org/10.1038/nrd3270
22. M.Leal, P.Sapra, S.A.Hurvitz, P.Senter, A.Wahl, M.Schutten, D.K.Shah, N.Haddish-Berhane, O.Kabbarah. Antibody-drug conjugates: an emerging modality for the treatment of cancer. Ann N Y Acad Sci 2014; 1321:41-54; PMID:25123209; dx.doi.org/10.1111/nyas.12499
23. N.Ferrara, K.J.Hillan, H.P.Gerber, W.Novotny. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391-400; PMID:15136787; dx.doi.org/10.1038/nrd1381
24. A.J.Michielsen, E.J.Ryan, J.N.O'Sullivan. Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment. Oncoimmunology 2012; 1:1445-7; PMID:23243624; dx.doi.org/10.4161/onci.21318
25. T.de La Motte Rouge, L.Galluzzi, K.A.Olaussen, Y.Zermati, E.Tasdemir, T.Robert, H.Ripoche, V.Lazar, P.Dessen, F.Harper A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 2007; 67:6253-62; PMID:17616683; dx.doi.org/10.1158/0008-5472.CAN-07-0538
26. R.M.Goldberg. Cetuximab. Nat Rev Drug Discov 2005; Suppl:S10-11; Available: http://www.ncbi.nlm.nih.gov/pubmed/?term=Goldberg+RM.+Cetuximab.+Nat+Rev+Drug+Discov+2005%3B+Suppl%3AS10-1; PMID:15962524; dx.doi.org/10.1038/nrd1728
27. Y.Kawaguchi, K.Kono, K.Mimura, H.Sugai, H.Akaike, H.Fujii. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007; 120:781-7; PMID:17096332; dx.doi.org/10.1002/ijc.22370
28. R.M.Srivastava, S.C.Lee, P.A.Andrade Filho, C.A.Lord, H.B.Jie, H.C.Davidson, A.López-Albaitero, S.P.Gibson, W.E.Gooding, S.Ferrone Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 2013; 19:1858-72; PMID:23444227; dx.doi.org/10.1158/1078-0432.CCR-12-2426
29. S.Derer, S.Lohse, T.Valerius. EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodies. Oncoimmunology 2013; 2:e24052; PMID:23762793; dx.doi.org/10.4161/onci.24052
30. B.D.Choi, P.C.Gedeon, L.Sanchez-Perez, D.D.Bigner, J.H.Sampson. Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. Oncoimmunology 2013; 2:e26757; PMID:24475376; dx.doi.org/10.4161/onci.26757
31. B.D.Choi, I.Pastan, D.D.Bigner, J.H.Sampson. A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system. Oncoimmunology 2013; 2:e23639; PMID:23734318; dx.doi.org/10.4161/onci.23639
32. D.Nagorsen, P.Kufer, P.A.Baeuerle, R.Bargou. Blinatumomab: a historical perspective. Pharmacol Ther 2012; 136:334-42; PMID:22940266; dx.doi.org/10.1016/j.pharmthera.2012.07.013
33. D.Nagorsen, P.A.Baeuerle. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 2011; 317:1255-60; PMID:21419116; dx.doi.org/10.1016/j.yexcr.2011.03.010
34. M.S.Topp, P.Kufer, N.Gokbuget, M.Goebeler, M.Klinger, S.Neumann, H.A.Horst, T.Raff, A.Viardot, M.Schmid Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29:2493-8; PMID:21576633; dx.doi.org/10.1200/JCO.2010.32.7270
35. M.S.Topp, N.Gokbuget, G.Zugmaier, E.Degenhard, M.E.Goebeler, M.Klinger, S.A.Neumann, H.A.Horst, T.Raff, A.Viardot Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012; 120:5185-7; PMID:23024237; dx.doi.org/10.1182/blood-2012-07-441030
36. R.B.Walter. Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia. Expert Rev Hematol 2014; 7:317-9; PMID:24617311; dx.doi.org/10.1586/17474086.2014.896190
37. J.F.Rossi, S.Negrier, N.D.James, I.Kocak, R.Hawkins, H.Davis, U.Prabhakar, X.Qin, P.Mulders, B.Berns. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 2010; 103:1154-62; PMID:20808314; dx.doi.org/10.1038/sj.bjc.6605872
38. S.A.Hunsucker, V.Magarotto, D.J.Kuhn, S.M.Kornblau, M.Wang, D.M.Weber, S.K.Thomas, J.J.Shah, P.M.Voorhees, H.Xie Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 2011; 152:579-92; PMID:21241278; dx.doi.org/10.1111/j.1365-2141.2010.08533.x
39. Y.C.Liu, K.Stone, F.van Rhee. Siltuximab for multicentric Castleman disease. Expert Rev Hematol 2014; 7:545-57; PMID:25110138; dx.doi.org/10.1586/17474086.2014.946402
40. R.Kurzrock, P.M.Voorhees, C.Casper, R.R.Furman, L.Fayad, S.Lonial, H.Borghaei, S.Jagannath, L.Sokol, S.Z.Usmani A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 2013; 19:3659-70; PMID:23659971; dx.doi.org/10.1158/1078-0432.CCR-12-3349
41. F.van Rhee, L.Fayad, P.Voorhees, R.Furman, S.Lonial, H.Borghaei, L.Sokol, J.Crawford, M.Cornfeld, M.Qi Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010; 28:3701-8; PMID:20625121; dx.doi.org/10.1200/JCO.2009.27.2377
42. F.van Rhee, R.S.Wong, N.Munshi, J.F.Rossi, X.Y.Ke, A.Fossa, D.Simpson, M.Capra, T.Liu, R.K.Hsieh Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2014; 15:966-74; PMID:25042199; dx.doi.org/10.1016/S1470-2045(14)70319-5
43. Y.Krupitskaya, H.A.Wakelee. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs 2009; 10:597-605; PMID:19513949
44. M.A.Shah. Gastrointestinal cancer: targeted therapies in gastric cancer-the dawn of a new era. Nat Rev Clin Oncol 2014; 11:10-11; PMID:24300880; dx.doi.org/10.1038/nrclinonc.2013.231
45. C.S.Fuchs, J.Tomasek, C.J.Yong, F.Dumitru, R.Passalacqua, C.Goswami, H.Safran, L.V.dos Santos, G.Aprile, D.R.Ferry Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383:31-9; PMID:24094768; dx.doi.org/10.1016/S0140-6736(13)61719-5
46. H.Wilke, K.Muro, E.Van Cutsem, S.C.Oh, G.Bodoky, Y.Shimada, S.Hironaka, N.Sugimoto, O.Lipatov, T.Y.Kim Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15:1224-35; PMID:25240821; dx.doi.org/10.1016/S1470-2045(14)70420-6
47. C.Owen, D.A.Stewart. Obinutuzumab for the treatment of lymphoproliferative disorders. Expert Opin Biol Ther 2012; 12:343-51; PMID:22283718; dx.doi.org/10.1517/14712598.2012.657622
48. L.Bologna, E.Gotti, M.Manganini, A.Rambaldi, T.Intermesoli, M.Introna, J.Golay. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011; 186:3762-9; PMID:21296976; dx.doi.org/10.4049/jimmunol.1000303
49. T.Robak. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs 2009; 10:588-96; PMID:19513948
50. H.Z.Lee, B.W.Miller, V.E.Kwitkowski, S.Ricci, P.DelValle, H.Saber, J.Grillo, J.Bullock, J.Florian, N.Mehrotra U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia. Clin Cancer Res 2014; 20:3902-7; PMID:24824310; dx.doi.org/10.1158/1078-0432.CCR-14-0516
51. K.R.Rai, J.C.Barrientos. Movement toward optimization of CLL therapy. N Engl J Med 2014; 370:1160-2; PMID:24645950; dx.doi.org/10.1056/NEJMe1400599
52. V.Goede, K.Fischer, R.Busch, A.Engelke, B.Eichhorst, C.M.Wendtner, T.Chagorova, J.de la Serna, M.S.Dilhuydy, T.Illmer Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370:1101-10; PMID:24401022; dx.doi.org/10.1056/NEJMoa1313984
53. H.Hurwitz, L.Fehrenbacher, W.Novotny, T.Cartwright, J.Hainsworth, W.Heim, J.Berlin, A.Baron, S.Griffing, E.Holmgren Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42; PMID:15175435; dx.doi.org/10.1056/NEJMoa032691
54. A.Sandler, R.Gray, M.C.Perry, J.Brahmer, J.H.Schiller, A.Dowlati, R.Lilenbaum, D.H.Johnson. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50; PMID:17167137; dx.doi.org/10.1056/NEJMoa061884
55. A.S.Mansfield, W.K.Nevala, E.A.Lieser, A.A.Leontovich, S.N.Markovic. The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. Oncoimmunology 2013; 2:e24436; PMID:23762809; dx.doi.org/10.4161/onci.24436
56. J.Hoffmann, I.Vitale, B.Buchmann, L.Galluzzi, W.Schwede, L.Senovilla, W.Skuballa, S.Vivet, R.B.Lichtner, J.M.Vicencio Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008; 68:5301-8; PMID:18593931; dx.doi.org/10.1158/0008-5472.CAN-08-0237
57. L.Senovilla, I.Vitale, I.Martins, O.Kepp, L.Galluzzi, L.Zitvogel, M.Castedo, G.Kroemer. An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells. Oncoimmunology 2013; 2:e22409; PMID:23482968; dx.doi.org/10.4161/onci.22409
58. I.Vitale, L.Galluzzi, M.Castedo, G.Kroemer. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 2011; 12:385-92; PMID:21527953; dx.doi.org/10.1038/nrm3115
59. K.S.Tewari, M.W.Sill, H.J.Long3rd, R.T.Penson, H.Huang, L.M.Ramondetta, L.M.Landrum, A.Oaknin, T.J.Reid, M.M.Leitao Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014; 370:734-43; PMID:24552320; dx.doi.org/10.1056/NEJMoa1309748
60. W.G.Wierda, T.J.Kipps, J.Mayer, S.Stilgenbauer, C.D.Williams, A.Hellmann, T.Robak, R.R.Furman, P.Hillmen, M.Trneny Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28:1749-55; PMID:20194866; dx.doi.org/10.1200/JCO.2009.25.3187
61. M.J.Keating, A.Dritselis, U.Yasothan, P.Kirkpatrick. Ofatumumab. Nat Rev Drug Discov 2010; 9:101-2; PMID:20118960; dx.doi.org/10.1038/nrd3100
62. S.J.Lemery, J.Zhang, M.D.Rothmann, J.Yang, J.Earp, H.Zhao, A.McDougal, A.Pilaro, R.Chiang, J.E.Gootenberg U.S. food and drug administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res 2010; 16:433-18; PMID:20601446; dx.doi.org/10.1158/1078-0432.CCR-10-0570
63. L.Boissel, M.Betancur-Boissel, W.Lu, D.S.Krause, R.A.Van Etten, W.S.Wels, H.Klingemann. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology 2013; 2:e26527; PMID:24404423; dx.doi.org/10.4161/onci.26527
64. R.Foa. Changes in the treatment landscape for chronic lymphoid leukemia. N Engl J Med 2014; 371:273-4; PMID:25014693; dx.doi.org/10.1056/NEJMe1405766
65. P.Hillmen, T.Robak, A.Janssens, K.Govindbabu, S.Grosicki, J.Mayer Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911). ASH Meeting Abstr 2013:528; Available: https://ash.confex.com/ash/2013/webprogram/Paper58498.html
66. L.Menger, E.Vacchelli, O.Kepp, A.Eggermont, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: cardiac glycosides and cancer therapy. Oncoimmunology 2013; 2:e23082; PMID:23525565; dx.doi.org/10.4161/onci.23082
67. L.Senovilla, E.Vacchelli, P.Garcia, A.Eggermont, W.H.Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2013; 2:e23803; PMID:23734328; dx.doi.org/10.4161/onci.23803
68. E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013; 2:e24238; PMID:23762803; dx.doi.org/10.4161/onci.24238
69. C.Krishnan, R.A.Warnke, D.A.Arber, Y.Natkunam. PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitis. Am J Surg Pathol 2010; 34:178-89; PMID:20087161; dx.doi.org/10.1097/PAS.0b013e3181cc7e79
70. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; dx.doi.org/10.1056/NEJMoa1003466
71. M.K.Erdmann. Immunity unleashed in melanoma. Lancet Oncol 2010; 11:108-9; PMID:20152761; dx.doi.org/10.1016/S1470-2045(09)70400-0
72. J.D.Wolchok, B.Neyns, G.Linette, S.Negrier, J.Lutzky, L.Thomas, W.Waterfield, D.Schadendorf, M.Smylie, T.GuthrieJr Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-64; PMID:20004617; dx.doi.org/10.1016/S1470-2045(09)70334-1
73. C.Robert, A.Ribas, J.D.Wolchok, F.S.Hodi, O.Hamid, R.Kefford, J.S.Weber, A.M.Joshua, W.J.Hwu, T.C.Gangadhar Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384:1109-17; PMID:25034862; dx.doi.org/10.1016/S0140-6736(14)60958-2
74. A.Ribas, F.S.Hodi, R.Kefford, O.Hamid, A.Daud, J.D.Wolchok Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). ASCO Meeting Abstr 2014; 32:LBA9000; Available: http://meetinglibrary.asco.org/content/133842-144
75. S.N.Linch, W.L.Redmond. Combined OX40 ligation plus CTLA-4 blockade: more than the sum of its parts. Oncoimmunology 2014; 3:e28245; PMID:25050194; dx.doi.org/10.4161/onci.28245
76. L.Calabro, M.Maio. Immune checkpoint blockade in malignant mesothelioma: a novel therapeutic strategy against a deadly disease? Oncoimmunology 2014; 3:e27482; PMID:24734215; dx.doi.org/10.4161/onci.27482
77. L.Robert, C.Harview, R.Emerson, X.Wang, S.Mok, B.Homet, B.Comin-Anduix, R.C.Koya, H.Robins, P.C.Tumeh Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology 2014; 3:e29244; PMID:25083336; dx.doi.org/10.4161/onci.29244
78. S.D.Scott. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract 1998; 6:195-7; PMID:9652253; dx.doi.org/10.1046/j.1523-5394.1998.006003195.x
79. B.Jones. Haematological cancer: rituximab maintenance improves the outcome of elderly patients with FL. Nat Rev Clin Oncol 2013; 10:607; PMID:23999211; dx.doi.org/10.1038/nrclinonc.2013.164
80. H.E.El-Osta, R.Kurzrock. Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist 2011; 16:497-511; PMID:21441298; dx.doi.org/10.1634/theoncologist.2010-0212
81. E.B.Garon, T.E.Ciuleanu, O.Arrieta, K.Prabhash, K.N.Syrigos, T.Goksel, K.Park, V.Gorbunova, R.D.Kowalyszyn, J.Pikiel Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384:665-73; PMID:24933332; dx.doi.org/10.1016/S0140-6736(14)60845-X
82. J.C.Byrd, R.R.Furman, S.E.Coutre, I.W.Flinn, J.A.Burger, K.A.Blum, B.Grant, J.P.Sharman, M.Coleman, W.G.Wierda Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369:32-42; PMID:23782158; dx.doi.org/10.1056/NEJMoa1215637
83. M.L.Wang, S.Rule, P.Martin, A.Goy, R.Auer, B.S.Kahl, W.Jurczak, R.H.Advani, J.E.Romaguera, M.E.Williams Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369:507-16; PMID:23782157; dx.doi.org/10.1056/NEJMoa1306220
84. J.C.Byrd, J.R.Brown, S.O'Brien, J.C.Barrientos, N.E.Kay, N.M.Reddy, S.Coutre, C.S.Tam, S.P.Mulligan, U.Jaeger Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371:213-23; PMID:24881631; dx.doi.org/10.1056/NEJMoa1400376
85. E.S.Kim, M.Neubauer, A.Cohn, L.Schwartzberg, L.Garbo, J.Caton, F.Robert, C.Reynolds, T.Katz, S.Chittoor Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol 2013; 14:1326-36; PMID:24231627; dx.doi.org/10.1016/S1470-2045(13)70473-X
86. E.Pujade-Lauraine, F.Hilpert, B.Weber, A.Reuss, A.Poveda, G.Kristensen, R.Sorio, I.Vergote, P.Witteveen, A.Bamias Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014; 32:1302-8; PMID:24637997; dx.doi.org/10.1200/JCO.2013.51.4489
87. G.von Minckwitz, F.Puglisi, J.Cortes, E.Vrdoljak, N.Marschner, C.Zielinski, C.Villanueva, G.Romieu, I.Lang, E.Ciruelos Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15:1269-78; PMID:25273342; dx.doi.org/10.1016/S1470-2045(14)70439-5
88. G.von Minckwitz, A.Schneeweiss, S.Loibl, C.Salat, C.Denkert, M.Rezai, J.U.Blohmer, C.Jackisch, S.Paepke, B.Gerber Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014; 15:747-56; PMID:24794243; dx.doi.org/10.1016/S1470-2045(14)70160-3
89. F.Navid, P.M.Sondel, R.Barfield, B.L.Shulkin, R.A.Kaufman, J.A.Allay, J.Gan, P.Hutson, S.Seo, K.Kim Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol 2014; 32:1445-52; PMID:24711551; dx.doi.org/10.1200/JCO.2013.50.4423
90. L.R.Desnoyers, O.Vasiljeva, J.H.Richardson, A.Yang, E.E.Menendez, T.W.Liang, C.Wong, P.H.Bessette, K.Kamath, S.J.Moore Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci Transl Med 2013; 5:207ra144; PMID:24132639; dx.doi.org/10.1126/scitranslmed.3006682
91. B.Q.Spring, A.O.Abu-Yousif, A.Palanisami, I.Rizvi, X.Zheng, Z.Mai, S.Anbil, R.B.Sears, L.B.Mensah, R.Goldschmidt Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates. Proc Natl Acad Sci U S A 2014; 111:E933-42; PMID:24572574; dx.doi.org/10.1073/pnas.1319493111
92. O.M.Pearce, H.Laubli, A.Verhagen, P.Secrest, J.Zhang, N.M.Varki, P.R.Crocker, J.D.Bui, A.Varki. Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. Proc Natl Acad Sci U S A 2014; 111:5998-6003; PMID:24711415; dx.doi.org/10.1073/pnas.1209067111
93. N.Gul, L.Babes, K.Siegmund, R.Korthouwer, M.Bogels, R.Braster, G.Vidarsson, T.L.ten Hagen, P.Kubes, M.van Egmond. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest 2014; 124:812-23; PMID:24430180; dx.doi.org/10.1172/JCI66776
94. F.Montalvao, Z.Garcia, S.Celli, B.Breart, J.Deguine, N.Van Rooijen, P.Bousso. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J Clin Invest 2013; 123:5098-103; PMID:24177426; dx.doi.org/10.1172/JCI70972
95. B.Li, Y.Meng, L.Zheng, X.Zhang, Q.Tong, W.Tan, S.Hu, H.Li, Y.Chen, J.Song Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization. Cancer Res 2013; 73:6471-83; PMID:24046294; dx.doi.org/10.1158/0008-5472.CAN-13-0657
96. C.Rossig. Extending the chimeric receptor-based T-cell targeting strategy to solid tumors. Oncoimmunology 2013; 2:e26091; PMID:24244901; dx.doi.org/10.4161/onci.26091
97. K.Kudo, C.Imai, P.Lorenzini, T.Kamiya, K.Kono, A.M.Davidoff, W.J.Chng, D.Campana. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res 2014; 74:93-103; PMID:24197131; dx.doi.org/10.1158/0008-5472.CAN-13-1365
98. H.E.Kohrt, A.D.Colevas, R.Houot, K.Weiskopf, M.J.Goldstein, P.Lund, A.Mueller, I.Sagiv-Barfi, A.Marabelle, R.Lira Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 2014; 124:2668-82; PMID:24837434; dx.doi.org/10.1172/JCI73014
99. H.E.Kohrt, A.Thielens, A.Marabelle, I.Sagiv-Barfi, C.Sola, F.Chanuc, N.Fuseri, C.Bonnafous, D.Czerwinski, A.Rajapaksa Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 2014; 123:678-86; PMID:24326534; dx.doi.org/10.1182/blood-2013-08-519199
100. L.Galluzzi, O.Kepp, M.G.Vander Heiden, G.Kroemer. Metabolic targets for cancer therapy. Nat Rev Drug Discov 2013; 12:829-46; PMID:24113830; dx.doi.org/10.1038/nrd4145
101. Z.Husain, P.Seth, V.P.Sukhatme. Tumor-derived lactate and myeloid-derived suppressor cells: linking metabolism to cancer immunology. Oncoimmunology 2013; 2:e26383; PMID:24404426; dx.doi.org/10.4161/onci.26383
102. G.Gondi, J.Mysliwietz, A.Hulikova, J.P.Jen, P.Swietach, E.Kremmer, R.Zeidler. Antitumor efficacy of a monoclonal antibody that inhibits the activity of cancer-associated carbonic anhydrase XII. Cancer Res 2013; 73:6494-503; PMID:24030978; dx.doi.org/10.1158/0008-5472.CAN-13-1110
103. A.P.Garner, C.U.Bialucha, E.R.Sprague, J.T.Garrett, Q.Sheng, S.Li, O.Sineshchekova, P.Saxena, C.R.Sutton, D.Chen An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res 2013; 73:6024-35; PMID:23928993; dx.doi.org/10.1158/0008-5472.CAN-13-1198
104. J.T.Garrett, C.R.Sutton, R.Kurupi, C.U.Bialucha, S.A.Ettenberg, S.D.Collins, Q.Sheng, J.Wallweber, L.Defazio-Eli, C.L.Arteaga. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110alpha inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Cancer Res 2013; 73:6013-23; PMID:23918797; dx.doi.org/10.1158/0008-5472.CAN-13-1191
105. J.J.Tao, P.Castel, N.Radosevic-Robin, M.Elkabets, N.Auricchio, N.Aceto, G.Weitsman, P.Barber, B.Vojnovic, H.Ellis Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal 2014; 7:ra29; PMID:24667376; dx.doi.org/10.1126/scisignal.2005125
106. E.C.Breij, B.E.de Goeij, S.Verploegen, D.H.Schuurhuis, A.Amirkhosravi, J.Francis, V.B.Miller, M.Houtkamp, W.K.Bleeker, D.Satijn An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res 2014; 74:1214-26; PMID:24371232; dx.doi.org/10.1158/0008-5472.CAN-13-2440
107. J.D.Graves, J.J.Kordich, T.H.Huang, J.Piasecki, T.L.Bush, T.Sullivan, I.N.Foltz, W.Chang, H.Douangpanya, T.Dang Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. Cancer Cell 2014; 26:177-89; PMID:25043603; dx.doi.org/10.1016/j.ccr.2014.04.028
108. J.L.Klitgaard, K.Koefoed, C.Geisler, O.V.Gadeberg, D.A.Frank, J.Petersen, M.W.Pedersen. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells. Br J Haematol 2013; 163:182-93; PMID:23927424
109. T.T.Junttila, J.Li, J.Johnston, M.Hristopoulos, R.Clark, D.Ellerman, B.E.Wang, Y.Li, M.Mathieu, G.Li Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res 2014; 74:5561-71; PMID:25228655; dx.doi.org/10.1158/0008-5472.CAN-13-3622-T
110. A.Grothey, E.Van Cutsem, A.Sobrero, S.Siena, A.Falcone, M.Ychou, Y.Humblet, O.Bouché, L.Mineur, C.Barone Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:303-12; PMID:23177514; dx.doi.org/10.1016/S0140-6736(12)61900-X
111. T.Eisen, H.Joensuu, P.D.Nathan, P.G.Harper, M.Z.Wojtukiewicz, S.Nicholson, A.Bahl, P.Tomczak, S.Pyrhonen, K.Fife Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol 2012; 13:1055-62; PMID:22959186; dx.doi.org/10.1016/S1470-2045(12)70364-9
112. V.A.Miller, V.Hirsh, J.Cadranel, Y.M.Chen, K.Park, S.W.Kim, C.Zhou, W.C.Su, M.Wang, Y.Sun Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012; 13:528-38; PMID:22452896; dx.doi.org/10.1016/S1470-2045(12)70087-6
113. J.C.Yang, J.Y.Shih, W.C.Su, T.C.Hsia, C.M.Tsai, S.H.Ou, C.J.Yu, G.C.Chang, C.L.Ho, L.V.Sequist Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012; 13:539-48; PMID:22452895; dx.doi.org/10.1016/S1470-2045(12)70086-4
114. J.Lu, L.Lee-Gabel, M.C.Nadeau, T.M.Ferencz, S.A.Soefje. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract 2014; Available: http://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+evaluation+of+compounds+targeting+PD-1%2FPD-L1+pathway+for+cancer+immunotherapy; PMID:24917416
115. C.J.Langer. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Am J Clin Oncol 2014; Available: http://www.ncbi.nlm.nih.gov/pubmed/?term=Emerging+Immunotherapies+in+the+Treatment+of+Non-Small+Cell+Lung+Cancer+(NSCLC)%3A+The+Role+of+Immune+Checkpoint+Inhibitors; PMID:24685885
116. B.C.Creelan. Update on immune checkpoint inhibitors in lung cancer. Cancer Control 2014; 21:80-9; PMID:24357746
117. S.Peirs, F.Matthijssens, S.Goossens, I.Van de Walle, K.Ruggero, C.E.de Bock, S.Degryse, K.Canté-Barrett, D.Briot, E.Clappier ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood 2014; 124(25):3738-47; PMID:25301704; dx.doi.org/10.1182/blood-2014-05-574566
118. ABT-199 Shows Effectiveness in CLL. Cancer Discov 2014; 4:OF7; dx.doi.org/10.1158/2159-8290.CD-NB2014-102
119. M.A.Anderson, D.Huang, A.Roberts. Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol 2014; 51:219-27; PMID:25048785; dx.doi.org/10.1053/j.seminhematol.2014.05.008
120. B.Nordlinger, H.Sorbye, B.Glimelius, G.J.Poston, P.M.Schlag, P.Rougier, W.O.Bechstein, J.N.Primrose, E.T.Walpole, M.Finch-Jones Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14:1208-15; PMID:24120480; dx.doi.org/10.1016/S1470-2045(13)70447-9
121. V.Yadav, T.F.Burke, L.Huber, R.D.Van Horn, Y.Zhang, S.G.Buchanan, E.M.Chan, J.J.Starling, R.P.Beckmann, S.B.Peng. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther 2014; 13:2253-63; PMID:25122067; dx.doi.org/10.1158/1535-7163.MCT-14-0257
122. L.M.Gelbert, S.Cai, X.Lin, C.Sanchez-Martinez, M.Del Prado, M.J.Lallena, M.J.Lallena, R.Torres, R.T.Ajamie, G.N.Wishart Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs 2014; 32:825-37; PMID:24919854; dx.doi.org/10.1007/s10637-014-0120-7
123. M.Uppenkamp, A.Engert, V.Diehl, D.Bunjes, D.Huhn, G.Brittinger. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. Ann Hematol 2002; 81:26-32; PMID:11807632; dx.doi.org/10.1007/s00277-001-0394-7
124. B.Schmitt, C.M.Wendtner, M.Bergmann, R.Busch, A.Franke, R.Pasold, R.Schlag, G.Hopfinger, W.Hiddemann, B.Emmerich Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia. Clin Lymphoma 2002; 3:26-35; PMID:12141952; dx.doi.org/10.3816/CLM.2002.n.008
125. A.Younes, U.Yasothan, P.Kirkpatrick. Brentuximab vedotin. Nat Rev Drug Discov 2012; 11:19-20; PMID:22212672; dx.doi.org/10.1038/nrd3629
126. P.D.Senter, E.L.Sievers. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012; 30:631-7; PMID:22781692; dx.doi.org/10.1038/nbt.2289
127. E.Lainey, A.Wolfromm, N.Marie, D.Enot, M.Scoazec, C.Bouteloup, C.Leroy, J.B.Micol, S.De Botton, L.Galluzzi Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia. Oncogene 2013; 32:4331-42; PMID:23085751; dx.doi.org/10.1038/onc.2012.469
128. S.Thepot, E.Lainey, T.Cluzeau, M.Sebert, C.Leroy, L.Ades, M.Tailler, L.Galluzzi, F.Baran-Marszak, H.Roudot Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia. Cell Cycle 2011; 10:2323-30; PMID:21654193; dx.doi.org/10.4161/cc.10.14.16399
129. K.E.Sand, K.P.Rye, B.Mannsaker, O.Bruserud, A.O.Kittang. Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients. Oncoimmunology 2013; 2:e23138; PMID:23525654; dx.doi.org/10.4161/onci.23138
130. M.Semeraro, E.Vacchelli, A.Eggermont, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: lenalidomide-based immunochemotherapy. Oncoimmunology 2013; 2:e26494; PMID:24482747; dx.doi.org/10.4161/onci.26494
131. M.Semeraro, L.Galluzzi. Novel insights into the mechanism of action of lenalidomide. Oncoimmunology 2014; 3:e28386; PMID:25340011; dx.doi.org/10.4161/onci.28386
132. R.M.Giusti, K.Shastri, A.M.Pilaro, C.Fuchs, R.Cordoba-Rodriguez, K.Koti, M.Rothmann, A.Y.Men, H.Zhao, M.Hughes U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 2008; 14:1296-302; PMID:18316547; dx.doi.org/10.1158/1078-0432.CCR-07-1354
133. J.R.Hecht, E.Mitchell, T.Chidiac, C.Scroggin, C.Hagenstad, D.Spigel, J.Marshall, A.Cohn, D.McCollum, P.Stella A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27:672-80; PMID:19114685; dx.doi.org/10.1200/JCO.2008.19.8135
134. R.G.Amado, M.Wolf, M.Peeters, E.Van Cutsem, S.Siena, D.J.Freeman, T.Juan, R.Sikorski, S.Suggs, R.Radinsky Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-34; PMID:18316791; dx.doi.org/10.1200/JCO.2007.14.7116
135. J.Baselga, J.Cortes, S.B.Kim, S.A.Im, R.Hegg, Y.H.Im, L.Roman, J.L.Pedrini, T.Pienkowski, A.Knott Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109-19; PMID:22149875; dx.doi.org/10.1056/NEJMoa1113216
136. L.Gianni, T.Pienkowski, Y.H.Im, L.Roman, L.M.Tseng, M.C.Liu, A.Lluch, E.Staroslawska, J.de la Haba-Rodriguez, S.A.Im Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13:25-32; PMID:22153890; dx.doi.org/10.1016/S1470-2045(11)70336-9
137. L.Galluzzi, L.Senovilla, I.Vitale, J.Michels, I.Martins, O.Kepp Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31:1869-83; PMID:21892204; dx.doi.org/10.1038/onc.2011.384
138. L.Galluzzi, I.Vitale, L.Senovilla, K.A.Olaussen, G.Pinna, T.Eisenberg, A.Goubar, I.Martins, J.Michels, G.Kratassiouk Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep 2012; 2:257-69; PMID:22854025; dx.doi.org/10.1016/j.celrep.2012.06.017
139. S.Chawla, R.Henshaw, L.Seeger, E.Choy, J.Y.Blay, S.Ferrari, J.Kroep, R.Grimer, P.Reichardt, P.Rutkowski Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013; 14:901-8; PMID:23867211; dx.doi.org/10.1016/S1470-2045(13)70277-8
140. D.G.Branstetter, S.D.Nelson, J.C.Manivel, J.Y.Blay, S.Chawla, D.M.Thomas, S.Jun, I.Jacobs. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012; 18:4415-24; PMID:22711702; dx.doi.org/10.1158/1078-0432.CCR-12-0578
141. R.E.Coleman. Bone cancer in 2011: prevention and treatment of bone metastases. Nat Rev Clin Oncol 2012; 9:76-8; PMID:22182971; dx.doi.org/10.1038/nrclinonc.2011.198
142. N.J.Shaw, C.M.Boivin, N.J.Crabtree. Intravenous pamidronate in juvenile osteoporosis. Arch Dis Child 2000; 83:143-5; PMID:10906023; dx.doi.org/10.1136/adc.83.2.143
143. A.Peretz, J.J.Body, J.C.Dumon, S.Rozenberg, A.Hotimski, J.P.Praet, M.Moris, H.Ham, P.Bergmann. Cyclical pamidronate infusions in postmenopausal osteoporosis. Maturitas 1996; 25:69-75; PMID:8887311; dx.doi.org/10.1016/0378-5122(96)01118-8
144. M.P.de Vetten, J.H.Jansen, B.A.van der Reijden, M.S.Berger, J.M.Zijlmans, B.Lowenberg. Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676). Br J Haematol 2000; 111:277-9; PMID:11091212; dx.doi.org/10.1046/j.1365-2141.2000.02402.x
145. E.L.Sievers, R.A.Larson, E.A.Stadtmauer, E.Estey, B.Lowenberg, H.Dombret, C.Karanes, M.Theobald, J.M.Bennett, M.L.Sherman Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19:3244-54; PMID:11432892
146. P.F.Bross, J.Beitz, G.Chen, X.H.Chen, E.Duffy, L.Kieffer, S.Roy, R.Sridhara, A.Rahman, G.Williams Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7:1490-6; PMID:11410481
147. F.McAleese, M.Eser. RECRUIT-TandAbs: harnessing the immune system to kill cancer cells. Future Oncol 2012; 8:687-95; PMID:22764766; dx.doi.org/10.2217/fon.12.54
148. E.Zhukovsky, U.Reusch, C.Burkhardt, S.Knackmuss, I.Fucek, M.Eser AFM11, a CD19/CD3 bispecific tandab, to facilitate T-cell-mediated killing of CD19+ cells. ASCO Meeting Abstr 2013; 31:3068. Available: http://meetinglibrary.asco.org/content/115108-132
149. E.Zhukovsky, S.Knackmuss, U.Reusch, C.Wall, K.Ellwanger, I.Fucek Preclinical development, primary and secondary phrmacodynamics, of the CD19/CD3 Tandab (AFM11). ASCO Meeting Abstr 2014; 32:e19546. Available: http://meetinglibrary.asco.org/content/133329-144
150. Y.Akashi, I.Okamoto, T.Iwasa, T.Yoshida, M.Suzuki, E.Hatashita, Y.Yamada, T.Satoh, M.Fukuoka, K.Ono Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 2008; 98:749-55; PMID:18253126; dx.doi.org/10.1038/sj.bjc.6604222
151. A.Casaco, G.Lopez, I.Garcia, J.A.Rodriguez, R.Fernandez, J.Figueredo, L.Torres, A.Perera, J.Batista, R.Leyva Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma. Cancer Biol Ther 2008; 7:333-9; PMID:18094616; dx.doi.org/10.4161/cbt.7.3.5414
152. G.Bebb, C.Smith, S.Rorke, W.Boland, L.Nicacio, R.Sukhoo, A.Brade. Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemother Pharmacol 2011; 67:837-45; PMID:20563810; dx.doi.org/10.1007/s00280-010-1379-9
153. M.S.Gordon, C.S.Sweeney, D.S.Mendelson, S.G.Eckhardt, A.Anderson, D.M.Beaupre, D.Branstetter, T.L.Burgess, A.Coxon, H.Deng Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 2010; 16:699-710; PMID:20068101; dx.doi.org/10.1158/1078-0432.CCR-09-1365
154. H.T.Jun, J.Sun, K.Rex, R.Radinsky, R.Kendall, A.Coxon, T.L.Burgess. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 2007; 13:6735-42; PMID:18006775; dx.doi.org/10.1158/1078-0432.CCR-06-2969
155. T.Kakkar, M.Ma, Y.Zhuang, A.Patton, Z.Hu, B.Mounho. Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys. Pharm Res 2007; 24:1910-8; PMID:17520181; dx.doi.org/10.1007/s11095-007-9316-2
156. E.Lainey, M.Sebert, S.Thepot, M.Scoazec, C.Bouteloup, C.Leroy, S.De Botton, L.Galluzzi, P.Fenaux, G.Kroemer. Erlotinib antagonizes ABC transporters in acute myeloid leukemia. Cell Cycle 2012; 11:4079-92; PMID:23095522; dx.doi.org/10.4161/cc.22382
157. S.Boehrer, L.Ades, T.Braun, L.Galluzzi, J.Grosjean, C.Fabre, G.Le Roux, C.Gardin, A.Martin, S.de Botton Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 2008; 111:2170-80; PMID:17925489; dx.doi.org/10.1182/blood-2007-07-100362
158. Le M.Garff-Tavernier, L.Herbi, C.de Romeuf, F.Nguyen-Khac, F.Davi, A.Grelier, M.Boudjoghra, K.Maloum, S.Choquet, R.Urbain Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. Leukemia 2014; 28:230-3; PMID:23958919; dx.doi.org/10.1038/leu.2013.240
159. Ben R.Abdelwahed, S.Donnou, H.Ouakrim, L.Crozet, J.Cosette, A.Jacquet, I.Tourais, B.Fournès, M.Gillard Bocquet, A.Miloudi Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas. Invest Ophthalmol Vis Sci 2013; 54:3657-65; PMID:23611989; dx.doi.org/10.1167/iovs.12-10316
160. L.Liu, W.Zeng, M.A.Wortinger, S.C.Yan, P.D.Cornwell, V.L.Peek, J.R.Stephens, J.W.Tetreault, J.Xia, J.R.Manro LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res 2014; 20:6059-70; PMID:25231402; dx.doi.org/10.1158/1078-0432.CCR-14-0543
161. D.Dornan, F.Bennett, Y.Chen, M.Dennis, D.Eaton, K.Elkins, D.French, M.A.Go, A.Jack, J.R.Junutula Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 2009; 114:2721-9; PMID:19633198; dx.doi.org/10.1182/blood-2009-02-205500
162. A.G.Polson, S.F.Yu, K.Elkins, B.Zheng, S.Clark, G.S.Ingle, D.S.Slaga, L.Giere, C.Du, C.Tan Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood 2007; 110:616-23; PMID:17374736; dx.doi.org/10.1182/blood-2007-01-066704
163. N.Tageja, J.Nagi. Bendamustine: something old, something new. Cancer Chemother Pharmacol 2010; 66:413-23; PMID:20376452; dx.doi.org/10.1007/s00280-010-1317-x
164. J.L.Murray, E.S.Kleinerman, S.F.Jia, M.G.Rosenblum, O.Eton, A.Buzaid, S.Legha, M.I.Ross, L.Thompson, K.Mujoo Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphasis Tumor Immunol 1996; 19:206-17; PMID:8811495; dx.doi.org/10.1097/00002371-199605000-00005
165. M.F.Ozkaynak, P.M.Sondel, M.D.Krailo, J.Gan, B.Javorsky, R.A.Reisfeld, K.K.Matthay, G.H.Reaman, R.C.Seeger. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol 2000; 18:4077-85; PMID:11118469
166. A.L.Yu, A.L.Gilman, M.F.Ozkaynak, W.B.London, S.G.Kreissman, H.X.Chen, M.Smith, B.Anderson, J.G.Villablanca, K.K.Matthay Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-34; PMID:20879881; dx.doi.org/10.1056/NEJMoa0911123
167. T.Simon, B.Hero, A.Faldum, R.Handgretinger, M.Schrappe, T.Klingebiel, F.Berthold. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer 2011; 11:21; PMID:21244693; dx.doi.org/10.1186/1471-2407-11-21
168. S.Modak, B.H.Kushner, K.Kramer, A.Vickers, I.Y.Cheung, N.K.Cheung. Anti-GD2 antibody 3F8 and barley-derived (1 -> 3),(1 -> 4)-beta-glucan: a phase I study in patients with chemoresistant neuroblastoma. Oncoimmunology 2013; 2:e23402; PMID:23802080
169. N.K.Cheung, H.Guo, J.Hu, D.V.Tassev, I.Y.Cheung. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology 2012; 1:477-86; PMID:22754766; dx.doi.org/10.4161/onci.19864
170. E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: immunostimulatory cytokines. Oncoimmunology 2013; 2:e24850; PMID:24073369; dx.doi.org/10.4161/onci.24850
171. E.Vacchelli, F.Aranda, F.Obrist, A.Eggermont, J.Galon, I.Cremer, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014; 3:e29030; PMID:25083328; dx.doi.org/10.4161/onci.29030
172. S.C.Jeffrey, P.J.Burke, R.P.Lyon, D.W.Meyer, D.Sussman, M.Anderson, J.H.Hunter, C.I.Leiske, J.B.Miyamoto, N.D.Nicholas A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem 2013; 24:1256-63; PMID:23808985; dx.doi.org/10.1021/bc400217g
173. M.Roselli, V.Cereda, M.G.di Bari, V.Formica, A.Spila, C.Jochems, B.Farsaci, R.Donahue, J.L.Gulley, J.Schlom Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology 2013; 2:e27025; PMID:24353914; dx.doi.org/10.4161/onci.27025
174. D.W.Miles, A.Chan, L.Y.Dirix, J.Cortes, X.Pivot, P.Tomczak, T.Delozier, J.H.Sohn, L.Provencher, F.Puglisi Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28:3239-47; PMID:20498403; dx.doi.org/10.1200/JCO.2008.21.6457
175. L.Galluzzi, E.Vacchelli, W.H.Fridman, J.Galon, C.Sautes-Fridman, E.Tartour, J.Zucman-Rossi, L.Zitvogel, G.Kroemer. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28-37; PMID:22720209; dx.doi.org/10.4161/onci.1.1.17938
176. P.J.Beltran, P.Mitchell, Y.A.Chung, E.Cajulis, J.Lu, B.Belmontes, J.Ho, M.M.Tsai, M.Zhu, S.Vonderfecht AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 2009; 8:1095-105; PMID:19366899; dx.doi.org/10.1158/1535-7163.MCT-08-1171
177. G.Kroemer, L.Galluzzi, O.Kepp, L.Zitvogel. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; dx.doi.org/10.1146/annurev-immunol-032712-100008
178. E.Vacchelli, L.Senovilla, A.Eggermont, W.H.Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013; 2:e23510; PMID:23687621; dx.doi.org/10.4161/onci.23510
179. B.Pro, R.Advani, P.Brice, N.L.Bartlett, J.D.Rosenblatt, T.Illidge, J.Matous, R.Ramchandren, M.Fanale, J.M.Connors Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30:2190-6; PMID:22614995; dx.doi.org/10.1200/JCO.2011.38.0402
180. K.P.McKian, P.Haluska. Cixutumumab. Expert Opin Investig Drugs 2009; 18:1025-33; PMID:19548856; dx.doi.org/10.1517/13543780903055049
181. R.Garcia-Carbonero, F.Rivera, J.Maurel, J.-P.M.Ayoub, M.J.Moore, A.Cervantes-Ruiperez, T.R.Asmis, J.D.Schwartz, F.Nasroulah, S.Ballal A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): CP12-0709/NCT00862784. ASCO Meeting Abstracts 2012; 30:533; PMID:24674871; dx.doi.org/10.1634/theoncologist.2014-0028
182. T.Yoshino, K.Yamazaki, M.Yoshida, M.D.Rutstein, N.Yoshizuka, A.Ohtsu. A phase (Ph) Ib study of irinotecan (IRI), levofolinate (LV), and 5-fluorouracil (5-FU) (FOLFIRI) plus ramucirumab (RAM; IMC-1121B) drug product in Japanese (JP) patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (CP12-1029/NCT01286818). ASCO Meeting Abstr 2013; 31:591.
183. M.J.Towle, K.A.Salvato, B.F.Wels, K.K.Aalfs, W.Zheng, B.M.Seletsky, X.Zhu, B.M.Lewis, Y.Kishi, M.J.Yu Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res 2011; 71:496-505; PMID:21127197; dx.doi.org/10.1158/0008-5472.CAN-10-1874
184. G.Kuznetsov, M.J.Towle, H.Cheng, T.Kawamura, K.TenDyke, D.Liu, Y.Kishi, M.J.Yu, B.A.Littlefield. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004; 64:5760-6; PMID:15313917; dx.doi.org/10.1158/0008-5472.CAN-04-1169
185. D.A.Yardley, P.D.Richards, J.A.Reeves, E.C.Dees, C.R.C.Osborne, H.H.Soliman Final results of a phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced metastatic breast cancer (MBC). ASCO Meeting Abstr 2014; 32:1035. Available: http://meetinglibrary.asco.org/content/126127-144
186. M.N.Stein, L.Q.M.Chow, D.C.Smith, D.R.Shepard, D.Wang, J.D.Powderly Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of docetaxel (DOC) in patients (pts) with advanced malignant solid tumors. ASCO Meeting Abstr 2014; 32:e13539.Available: http://meetinglibrary.asco.org/content/126489-144
187. A.F.Shaughnessy. Monoclonal antibodies: magic bullets with a hefty price tag. BMJ 2012; 345:e8346; PMID:23236036; dx.doi.org/10.1136/bmj.e8346
188. J.Pol, N.Bloy, F.Obrist, A.Eggermont, J.Galon, W.Herve Fridman, I.Cremer, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2014; 3:e28185; PMID:24800178; dx.doi.org/10.4161/onci.28185
189. F.Aranda, E.Vacchelli, A.Eggermont, J.Galon, C.Sautes-Fridman, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2013; 2:e26621; PMID:24498550; dx.doi.org/10.4161/onci.26621
190. L.Reslan, S.Dalle, C.Dumontet. Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs 2009; 1:222-9; PMID:20065642; dx.doi.org/10.4161/mabs.1.3.8292
191. C.W.Shuptrine, R.Surana, L.M.Weiner. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol 2012; 22:3-13; PMID:22245472; dx.doi.org/10.1016/j.semcancer.2011.12.009
192. A.M.Scott, J.D.Wolchok, L.J.Old. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87; PMID:22437872; dx.doi.org/10.1038/nrc3236
193. T.T.Hansel, H.Kropshofer, T.Singer, J.A.Mitchell, A.J.George. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010; 9:325-38; PMID:20305665; dx.doi.org/10.1038/nrd3003